Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 65 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IVT Aflibercept Clear all
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

NCT06856577
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
75
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Sep 30, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

NCT05161806
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
SOK583A1 (40 mg/mL), Prefilled Syringe (PFS)
Drug · Device
Lead sponsor
Sandoz
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Marietta, Georgia • Oak Forest, Illinois • Liverpool, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Sep 30, 2026, 2:15 AM EDT
Active, not recruiting Phase 4 Interventional

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

NCT07118670
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy (PDR)
Interventions
Aflibercept 8mg
Drug
Lead sponsor
Edward Wood, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Austin, Texas • Bellaire, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 30, 2026, 2:15 AM EDT
Completed Phase 2 Interventional

Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

NCT07501052
View directory record Official record
Conditions
Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
SCD411 0.05mL (2mg)
Drug
Lead sponsor
Sam Chun Dang Pharm. Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Stuart, Florida • Winter Haven, Florida • Lemont, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 30, 2026, 2:15 AM EDT
Completed Phase 4 Interventional

Ocular Safety and Usability Study for FYB203 PFS

NCT06708637
View directory record Official record
Conditions
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
FYB203 2 mg (0.05 mL of 40 mg/mL)
Drug
Lead sponsor
Formycon AG
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Campbell, California • Long Beach, California • Redlands, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Sep 30, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD

NCT00527423
View directory record Official record
Conditions
Macular Degeneration
Interventions
VEGF Trap Eye
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
33
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Sep 30, 2026, 2:15 AM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02980874
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Sep 30, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome

NCT01578720
View directory record Official record
Conditions
Choroidal Neovascularization, Presumed Ocular Histoplasmosis
Interventions
EYLEA (Aflibercept) intravitreal injection
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Sep 30, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

NCT04740931
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 30, 2026, 2:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

NCT06550011
View directory record Official record
Conditions
Neovascular (Wet) AMD
Interventions
ABI-110 Low Dose, ABI-110 Medium Dose, ABI-110 High Dose
Drug
Lead sponsor
Avirmax Biopharma Inc
Industry
Eligibility
50 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
4
States / cities
Bakersfield, California • Walnut Creek, California • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 30, 2026, 2:15 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

NCT07482176
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
79
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 30, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD

NCT03953079
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Drug: GB-102, Aflibercept
Drug
Lead sponsor
Graybug Vision
Industry
Eligibility
50 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
33
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Sep 30, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of RTH258 Versus Aflibercept - Study 1

NCT02307682
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
1,775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 30, 2026, 2:15 AM EDT
Completed No phase listed Observational

A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

NCT06769412
View directory record Official record
Conditions
Retinal Vasculitis
Interventions
aflibercept 2 mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 30, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

NCT02718326
View directory record Official record
Conditions
Nonproliferative Diabetic Retinopathy
Interventions
Intravitreal aflibercept injection [IAI], Sham
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 30, 2026, 2:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05769153
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant, Aflibercept Injection, Sham procedure
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
42
States / cities
Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 30, 2026, 2:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

NCT06491914
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions
Aflibercept 8 mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
53
States / cities
Arcadia, California • Bakersfield, California • Beverly Hills, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Sep 30, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT04740905
View directory record Official record
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 30, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

NCT05282004
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
SOK583A1
Drug
Lead sponsor
Sandoz
Industry
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
5
States / cities
Poway, California • Marietta, Georgia • Oak Forest, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Sep 30, 2026, 2:15 AM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

NCT07705555
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
MK-8748, Aflibercept
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Glendale, California • Denver, Colorado • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 30, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

NCT04126317
View directory record Official record
Conditions
Neovascular (Wet) Age-Related Macular Degeneration
Interventions
aflibercept, High-dose aflibercept
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
45
States / cities
Phoenix, Arizona • Sun City, Arizona • Encino, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 30, 2026, 2:15 AM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

NCT06850922
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
RO7446603, Aflibercept, Faricimab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
70
States / cities
Phoenix, Arizona • Springdale, Arkansas • Campbell, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 30, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

NCT04423718
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
1,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Sep 30, 2026, 2:15 AM EDT
Withdrawn Phase 4 Interventional

Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye

NCT04702048
View directory record Official record
Conditions
Retinopathy, Diabetic
Interventions
Aflibercept Injection, Sham injection
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 30, 2026, 2:15 AM EDT